Comparative Pharmacology
Head-to-head clinical analysis: DELTA CORTEF versus OTOCORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELTA CORTEF versus OTOCORT.
DELTA-CORTEF vs OTOCORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid; binds to glucocorticoid receptors, modulating gene expression to suppress inflammation, immune response, and adrenal function.
Otocort is a combination product containing hydrocortisone (a corticosteroid), neomycin (an aminoglycoside antibiotic), and polymyxin B (a polymyxin antibiotic). Hydrocortisone suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis. Neomycin binds to bacterial 30S ribosomal subunit, inhibiting protein synthesis. Polymyxin B disrupts bacterial cell membrane permeability by binding to lipopolysaccharides.
Prednisolone (DELTA-CORTEF) typical adult dose: 5-60 mg orally once daily or in divided doses, depending on condition. For acute exacerbations: 20-60 mg orally daily. Route: oral. Frequency: once daily or divided.
1-2 drops into affected ear(s) twice daily; otic route.
None Documented
None Documented
Terminal elimination half-life: 1.5-2.5 hours (mean ~2 hours) for prednisolone; clinical context: short-acting glucocorticoid, requires multiple daily dosing for sustained anti-inflammatory effect, adrenocortical suppression lasts approximately 1.25-1.5 days after discontinuation.
Hydrocortisone: plasma half-life 1.5-2 hours, biological half-life 8-12 hours due to intracellular receptor binding. Neomycin: terminal half-life 2-4 hours in patients with normal renal function; may prolong to 12-24 hours in renal impairment. Polymyxin B: terminal half-life 6-8 hours in normal renal function; significantly prolonged in renal failure (up to 2-3 days). Clinical context: Topical/otic application yields negligible systemic concentrations, so half-life is relevant only if significant absorption occurs (e.g., damaged tympanic membrane).
Renal: approximately 80-90% as unchanged drug and metabolites (primarily 20β-dihydrocortisone and other inactive conjugates); biliary/fecal: <10%.
Otocort is a combination product containing hydrocortisone, neomycin, and polymyxin B. The corticosteroid component undergoes hepatic metabolism with renal excretion of metabolites (<5% unchanged). Neomycin is minimally absorbed (3-6% from intact skin, higher from wounds) and excreted renally as unchanged drug (30-50%) and metabolites. Polymyxin B is not significantly absorbed through intact skin or tympanic membrane; systemic absorption negligible. Renal excretion of polymyxin B is slow (40-60% over 72 hours) via glomerular filtration. Fecal elimination accounts for <5% of absorbed dose for all components.
Category C
Category C
Corticosteroid
Otic Antibiotic/Corticosteroid